In their July 23rd 2014 press release (http://www.resverlogix.com/media/press-release.html?id=505#.VVo_zpNVhHw) Resverlogix alluded to doing several more assays in samples collected from patients treated w/ or w/o RVX-208 for 4 weeks in their pre-diabetes trial (https://clinicaltrials.gov/ct2/show/NCT01728467?term=rvx-208&rank=1)

"Analysis of data from the new trial beyond preliminary results reported here will include; HDL abundance, lipidomics, platelet aggregation, monocyte activation and neutrophil adhesion."

This HDL lipidomic abstract that will be presented at IAS next week exemplifies that they are following through on this and continuing to learn more and more about both short-term and long-term RVX-208 treatment and the many ways that it is beneficially impacting health.